[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100461778":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":43,"responsibleParty":56,"collaborators":58,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":84,"sex":89,"minAge":90,"maxAge":25,"enrollmentInfo":91,"targetDuration":25,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":101,"overallStatus":46,"whyStopped":25,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"Universitätsklinikum Hamburg-Eppendorf","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Early rhythm control therapy","EXPERIMENTAL","Patients with acute ischemic stroke and AF will receive either catheter ablation (mainly pulmonary vein isolation), or adequate antiarrhythmic drug therapy at an early time point. The initial therapy will be selected by the local investigator. In case of continuation or recurrence of AF, both modalities may be combined.",[13],"Other: Medical or interventional therapy for rhythm control in atrial fibrillation (antiarrhythmic drugs, ablation, electric cardio version)",{"label":15,"type":16,"description":17,"interventionNames":18},"Usual care","ACTIVE_COMPARATOR","Patients with acute ischemic stroke and AF will receive usual care following the current ESC guidelines for AF treatment.",[19],"Other: Usual care for atrial fibrillation",[21,26],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"Medical or interventional therapy for rhythm control in atrial fibrillation (antiarrhythmic drugs, ablation, electric cardio version)","Therapy for early rhythm control will be either by use of approved antiarrhythmic drugs (e.g. amiodarone, dronedarone, flecainide, propafenone), approved approaches and devices for ablation, or electric cardio version.",[9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Usual care for atrial fibrillation","Usual care for atrial fibrillation according to current guidelines. Usual care will mainly comprise rate control by approved drugs. We expect, that usual care will also comprise therapy for rhythm control in a small group of patients.",[15],[31],{"name":32,"affiliation":5,"role":33},"Götz Thomalla, MD","PRINCIPAL_INVESTIGATOR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Märit Jensen, MD","CONTACT","+4940741053770","m.jensen@uke.de",{"name":32,"role":37,"phone":41,"phoneExt":25,"email":42},"+4940741050137","thomalla@uke.de",[44],{"facility":45,"status":46,"city":47,"state":25,"zip":25,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":25},"University Medical Center Hamburg-Eppendorf","RECRUITING","Hamburg","Germany","DE",{"type":51,"coordinates":52},"Point",[53,54],9.99302,53.55073,{"lat":54,"lon":53},{"type":57,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[59,62,64,66,68,70,72,74,76,78,80],{"name":60,"class":61},"University Heart & Vascular Center Hamburg, Department of Cardiology","UNKNOWN",{"name":63,"class":61},"Department of Neurology, Royal Melbourne Hospital",{"name":65,"class":61},"Melbourne Heart Centre, Royal Melbourne Hospital",{"name":67,"class":6},"Hotchkiss Brain Institute, University of Calgary",{"name":69,"class":61},"Department of Neurology and Neurosurgery, Brain Center, University Medical Center Utrecht",{"name":71,"class":6},"UMC Utrecht",{"name":73,"class":61},"Edinburgh Clinical Trials Unit, Cerebrovascular Research Group, Centre for Clinical Brain Sciences, University of Edinburgh",{"name":75,"class":61},"Department of Cardiovascular Sciences, University of Leicester British Heart Foundation Cardiovascular Research Centre",{"name":77,"class":61},"CTC-NORTH",{"name":79,"class":61},"Stroke Alliance for Europe (SAFE)",{"name":81,"class":61},"Kompetenznetz Vorhofflimmern e.V. (AFNET)","100461778","phase-3-early-treatment-of-atrial-fibrillation-for-stroke-prevention-trial-in-acute-stroke-100461778",false,"NCT05293080","Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE","EAST-STROKE","Inclusion Criteria:\n\n* Acute ischemic stroke in the previous four weeks, diagnosed by imaging (CT or MRI) or clinical diagnosis\n* Possibility to start the trial treatment within 4 weeks after stroke, and as soon as clinically justifiable\n* AF first detected ≤1 year prior to randomization\n* Informed consent\n\nExclusion Criteria:\n\n* End-stage cancer or life-expectancy \\\u003C 12 months due to other advanced co-morbid illness\n* Prior AF ablation or surgical therapy of AF\n* Patients not suitable for rhythm control of AF due to cardiac conditions","ALL","18 Years",{"count":92,"type":93},1746,"ESTIMATED","INTERVENTIONAL",[96],"PHASE3","This study will determine whether early, comprehensive, rhythm control therapy prevents adverse cardiovascular outcome in patients with acute ischemic stroke and atrial fibrillation compared to usual care.",[99,100],"Acute Ischemic Stroke","Atrial Fibrillation",[102,103,104,105,106],"Acute ischemic stroke","Atrial fibrillation","Rhythm control","Ablation","Antiarrhythmic drugs","2026-05-14",{"date":109,"type":110},"2026-05-18","ACTUAL",{"date":112,"type":110},"2025-11-06",{"date":114,"type":93},"2031-09",{"name":5,"class":6},1]